Finally, a PBS listing after 1514 days

 Posted 28 April 2025 PM

Johnson & Johnson's Spravato has become the first new type of medicine for major depression to be funded by the Federal Government in 30 years - after a punishing 1514 day battle for reimbursement.

From 1 May, Spravato will be available through the PBS for adults with treatment-resistant depression - a major depressive disorder which has not responded adequately to at least two different antidepressants of adequate dose and duration to treat the current moderate to severe depressive episode. It is used in conjunction with a newly-initiated oral antidepressant.

To see the whole article, please login